Berotralstat
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Drug reference
Tedizolid
Second-generation oxazolidinone antibiotic · Antibiotic
Also known as Tedizolid phosphate, Sivextro
START
200 mg PO/IV once daily for 6 days
TYPICAL MAX
200 mg/day
STOP IF
Severe hypersensitivity or C. difficile colitis
WATCH
CBC if prolonged use; serotonergic symptoms; CDI
CDSCO approvedSchedule HATC J01XX11
KDIGO 2024 + manufacturer label
- ONSET
- 1h · absorption
- PEAK
- 3h · Tmax
- t½
- 12h · t½
- DURATION
- 1d · once-daily
EXCRETION
Mainly faecal; ~18% renal
route + CYP
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
Use only if benefit outweighs risk; limited data.
FDA category + note
Top interactionssee all 4 →
- BerotralstatSevereDatabaseDDInter
- OzanimodSevereDatabaseDDInter
Mechanism
Binds the bacterial 23S rRNA of the 50S ribosomal subunit, inhibiting protein synthesis; active against Gram-positive organisms including MRSA, VRE; less myelosuppression vs linezolid.
Indications
Acute bacterial skin and skin-structure infections (Gram-positive, including MRSA)
Dosing
- Adult
- 200 mg PO or IV once daily for 6 days.
- Pediatric
- ≥12 y: same as adult; <12 y not established.
- Renal adjustment
- No adjustment for any eGFR.
- Hepatic adjustment
- No adjustment for any hepatic impairment.
- Geriatric
- No specific adjustment.
- Max dose
- 200 mg/day for 6 days
Pharmacokinetics
Onset
Bactericidal effect within hours
Peak effect
~3 h (Tmax oral)
Duration
~24 h (once-daily)
Half-life
~12 h
Bioavailability
~91% (oral)
Protein binding
~70–90%
Metabolism
Sulphation (no CYP involvement)
Excretion
Mainly faecal; ~18% renal
Contraindications
- Severe hypersensitivity to oxazolidinones
- Caution: serotonergic drugs (less than linezolid but mild MAOI activity)
Side effects
Common
Nausea/vomitingHeadacheDiarrhoeaDizzinessInsomnia
Serious
- Severe hypersensitivity
- C. difficile colitis
- Myelosuppression (less than linezolid)
- Peripheral/optic neuropathy (rare, prolonged use)
- Serotonin syndrome (theoretical, limited data)
Pregnancy & lactation
Pregnancy
Use only if benefit outweighs risk; limited data.
Lactation
Limited data; weigh benefit/risk.
Drug interactions
Ozanimod
Severe
Database
Clinical effect not specified
Source: DDInter
Bcrp Substrates
Moderate
Database
Tedizolid BCRP inhibition
Avoid co-administration if possible
Source: Kimi deep-research + Cla
Serotonergic Drugs
Moderate
Database
Tedizolid has weaker MAOI activity than linezolid
Monitor; avoid if possible
Source: Kimi deep-research + Cla
8 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about Tedizolid
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20